Tag Archives: David Jackson

GSK’s Depemokimab Cuts Severe Asthma Attacks by Over 50% in Phase III Trials

Posted on 10, September 2024 by

(IN BRIEF) GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and SWIFT-2 phase III trials. Administered every six months, it also demonstrated a 72% reduction in hospitalizations and emergency visits, offering … Read the full press release →

Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom

Tagged , , , , , , ,